Item 7.01 Regulation FD Disclosure

As previously disclosed, Tengion, Inc. (the "Company") is actively recruiting patients for its Phase I clinical trial of its Neo-Urinary Conduit product candidate and enrolling the remaining four patients for this trial. In light of the anticipated timing of enrolling patient seven in this trial, the Company anticipates that it will complete enrollment of the remaining patients during the first quarter of 2013.

Item 8.01 Other Events

On November 30, 2012, the Company sent a notice to holders of its senior secured convertible notes issued on October 2, 2012 that, the Company intends to issue shares of freely tradable common stock (the "Interest Shares") in lieu of the interest payments due on January 1, 2013. The issuance of the Interest Shares is contingent upon a registration statement covering the issuance or resale of the Interest Shares being declared effective by the Securities and Exchange Commission by January 1, 2013. If such a registration statement is not declared effective by January 1, 2013, the Company intends to make the interest payments in cash.

---